粒细胞集落刺激因子给药后血小板-淋巴细胞比值:化疗所致发热性中性粒细胞减少脓毒性休克患者的早期预后标志物
该研究从前瞻性脓毒性休克登记数据库中提取2012年6月至2017年6月连续收治的成年脓毒性休克合并化疗所致发热性中性粒细胞减少、接受G-CSF治疗的患者资料。共158例FN患者接受G-CSF,114例(72.2%)存活至1个月。入院时各项临床及系列实验室指标均不能显著预测生存;G-CSF给药后PLR和APACHE II为1个月生存的独立预测因子。G-CSF给药后PLR>100的aOR为9.394(95%CI 2.821-31.285,P<0.001),灵敏度89.4%、特异度46.2%、PPV 82.9%、NPV 60.0%;APACHE II<28的aOR为6.944(95%CI 2.351-20.511,P<0.001),灵敏度86.8%、特异度63.6%、PPV 86.1%、NPV 65.1%。作者认为G-CSF给药后PLR可能作为死亡率的早期预后标志物。
要点
- 化疗所致FN的脓毒性休克患者中,G-CSF给药后PLR>100预测1个月生存的aOR为9.394(95%CI 2.821-31.285,P<0.001),灵敏度89.4%、特异度46.2%。
- G-CSF给药后APACHE II<28预测1个月生存的aOR为6.944(95%CI 2.351-20.511,P<0.001),灵敏度86.8%、特异度63.6%。
- 入院时(G-CSF给药前)各项临床及系列实验室指标均不能显著预测生存。
- 158例接受G-CSF的FN脓毒性休克患者中114例(72.2%)存活至1个月。
- 作者认为G-CSF给药后PLR可能作为脓毒性休克合并化疗所致FN患者的早期预后标志物。
适用人群与场景
- 成年脓毒性休克合并化疗所致发热性中性粒细胞减少、接受G-CSF治疗的患者,数据来自2012年6月至2017年6月前瞻性脓毒性休克登记数据库中的连续病例。
诊断标准与关键阈值
- G-CSF给药后PLR>100用于预测1个月生存:灵敏度89.4%、特异度46.2%、PPV 82.9%、NPV 60.0%,aOR 9.394(95%CI 2.821-31.285,P<0.001)。
- G-CSF给药后APACHE II<28用于预测1个月生存:灵敏度86.8%、特异度63.6%、PPV 86.1%、NPV 65.1%,aOR 6.944(95%CI 2.351-20.511,P<0.001)。
研究设计与关键结果
- 研究类型为基于前瞻性脓毒性休克登记数据库的分析,共1671例脓毒性休克患者,其中158例化疗所致FN患者接受G-CSF治疗,114例(72.2%)存活至1个月。
- 入院时临床及系列实验室数据在非存活者与1个月存活者组间均无显著预测价值。
- G-CSF给药后PLR和APACHE II为1个月生存的独立预测因子:PLR>100的aOR 9.394(95%CI 2.821-31.285,P<0.001),APACHE II<28的aOR 6.944(95%CI 2.351-20.511,P<0.001)。
证据类型、等级与局限
- 证据类型:基于前瞻性脓毒性休克登记数据库的分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对化疗所致FN的脓毒性休克患者,G-CSF给药后PLR可能作为死亡率的早期预后标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Chemotherapy-induced febrile neutropenia (FN) causes life-threatening complications, but little is known in septic shock patients with FN. The aim of this study was to investigate the prognostic value of inflammatory markers, including C-reactive protein level, immature granulocyte count, white blood cell (WBC) count, absolute neutrophil count (ANC), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR), in septic shock patients with FN at admission and after granulocyte colony-stimulating factor (G-CSF) administration.
METHODS: Data on consecutive adult septic shock patients with FN treated with G-CSF between June 2012 and June 2017 were extracted from a prospectively compiled septic shock registry. Clinical and serial laboratory data at admission and <24 h after G-CSF administration were compared between nonsurvivor and 1-month survivor groups.
RESULTS: Of 1,671 septic shock patients, 158 FN patients were treated with G-CSF and 114 (72.2%) survived for 1 month. At admission, no clinical and serial laboratory data were significant to predict survival. After G-CSF administration, PLR and APACHE II were independent predictors for 1-month survival. PLR after administration of G-CSF >100 (adjusted odds ratio [aOR], 9.394; 95% CI, 2.821-31.285, P < 0.001) showed sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 89.4%, 46.2%, 82.9%, and 60.0%, respectively, and APACHE II <28 (aOR, 6.944; 95% CI, 2.351-20.511, P < 0.001) showed sensitivity, specificity, PPV, and NPV of 86.8%, 63.6%, 86.1%, and 65.1%, respectively.
CONCLUSIONS: After G-CSF administration in septic shock patients with chemotherapy-induced FN, PLR may be used as an early prognostic marker for mortality.
参考来源
- Kim YJ, Kang J, Ryoo SM, et al. Platelet-lymphocyte Ratio After Granulocyte Colony Stimulating Factor Administration: an Early Prognostic Marker in Septic Shock Patients With Chemotherapy-Induced Febrile Neutropenia. Shock. 2019. PMID: 30148761. doi:10.1097/SHK.0000000000001256
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。